Source:http://linkedlifedata.com/resource/pubmed/id/15103317
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2004-4-22
|
pubmed:abstractText |
Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. We have constructed retroviral and adenoviral vectors that express murine N-terminal fragments of thrombospondin-2 (NfTSP2), a potent endogenous inhibitor of tumor growth and angiogenesis. To test the possibility of anticancer gene therapy using NfTSP2, we tested whether an ex vivo retrovirus-mediated procedure could be used for the treatment of tumors. The treatment of tumor-bearing mice with syngenic immortalized cell lines expressing NfTSP2 led to a tumor volume reduction up to 70% as compared with the controls (P<0.005). In addition, the established tumors were eradicated in 40% of the mice treated with NfTSP2-expressing cells. Furthermore, the intratumoral injection of the NfTSP2-expressing adenoviral vector to the human squamous cell carcinoma in nude mice resulted in a significant reduction of the growth rates and the volumes of the carcinoma (P<0.05). Immunohistochemical staining of the tumors indicated that the total area and the average size of tumor vessels were significantly reduced in the treatment group versus the controls (P<0.05). In conclusion, the present study clearly demonstrates that the viral vector-mediated transfer of the NfTSP2 gene could inhibit the growth of tumors by perturbing tumor-associated angiogenesis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0969-7128
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
739-45
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15103317-Adenoviridae,
pubmed-meshheading:15103317-Animals,
pubmed-meshheading:15103317-Carcinoma, Squamous Cell,
pubmed-meshheading:15103317-DNA, Complementary,
pubmed-meshheading:15103317-Gene Therapy,
pubmed-meshheading:15103317-Genetic Vectors,
pubmed-meshheading:15103317-Humans,
pubmed-meshheading:15103317-Mice,
pubmed-meshheading:15103317-Mice, Inbred BALB C,
pubmed-meshheading:15103317-Mice, Nude,
pubmed-meshheading:15103317-Neoplasm Transplantation,
pubmed-meshheading:15103317-Neoplasms, Experimental,
pubmed-meshheading:15103317-Neovascularization, Pathologic,
pubmed-meshheading:15103317-Retroviridae,
pubmed-meshheading:15103317-Thrombospondins,
pubmed-meshheading:15103317-Transduction, Genetic,
pubmed-meshheading:15103317-Tumor Cells, Cultured
|
pubmed:year |
2004
|
pubmed:articleTitle |
Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis.
|
pubmed:affiliation |
ViroMed Co., Ltd, BongCheon-dong, KwanAk-gu, Seoul, Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|